def14a
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.___)
Filed by the Registrant
þ
Filed by a Party other than the Registrant o
Check the appropriate box:
|
|
|
þ |
|
Definitive Proxy Statement |
|
|
|
|
o |
|
Preliminary Proxy Statement |
|
|
|
|
o |
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
|
|
o |
|
Definitive Additional Materials |
|
|
|
|
o |
|
Soliciting Material Pursuant to §240.14a-12 |
Chad Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
|
|
|
þ |
No
fee required. |
|
|
|
|
o |
Fee
computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. |
|
|
|
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
|
|
|
|
(2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
|
|
|
|
(3)
|
|
Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (set forth the
amount on which the filing fee is calculated and state how it
was determined):
|
|
|
|
|
|
|
(4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
|
|
|
|
(5)
|
|
Total fee paid:
|
|
|
|
|
o |
|
Fee paid previously with preliminary materials. |
|
|
|
|
o |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the
filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing. |
|
|
|
|
|
|
(1)
|
|
Amount Previously Paid:
|
|
|
|
|
|
|
(2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
|
|
|
|
(3)
|
|
Filing Party:
|
|
|
|
|
|
|
(4)
|
|
Date Filed:
|
TABLE OF CONTENTS
CHAD THERAPEUTICS, INC.
NOTICE OF ANNUAL SHAREHOLDERS MEETING
To be held October 25, 2006
The Annual Meeting of Shareholders of CHAD Therapeutics, Inc. (the Company) will be held at the
Hilton Woodland Hills Hotel, 6360 Canoga Avenue, Woodland Hills, CA 91367, on October 25, 2006, at
10:00 a.m., Los Angeles time (the Meeting), for the following purposes:
1. To elect three (3) directors of the Company to the 2007 Class to serve during the ensuing two
(2) years or until their successors have been duly elected and qualified. The Board of Directors
nominees for election are Thomas E. Jones, John C. Boyd, and Earl L. Yager;
2. To ratify the appointment of KPMG LLP, certified public accountants, as independent auditors;
and
3. To transact such other business as may properly come before the Meeting and any adjournments
thereof.
Pursuant to the Bylaws of the Company, the Board of Directors has fixed September 8, 2006, as the
record date for the determination of such shareholders entitled to notice of and to vote at the
Meeting, and all adjournments thereof, and only shareholders of record at the close of business on
that date are entitled to such notice and to vote at the Meeting.
We hope that you will use this opportunity to take an active part in the affairs of the Company by
voting on the business to come before the Meeting by executing and returning the enclosed proxy.
Whether or not you expect to attend the Meeting in person, please date and sign the accompanying
proxy and return it promptly in the envelope enclosed for that purpose. If a shareholder receives
more than one (1) proxy because he owns shares registered in different names or addresses, each
proxy should be completed and returned.
|
|
|
|
|
By Order of the Board of Directors |
|
|
|
|
|
PAULA OCONNOR
Secretary |
Chatsworth, California
September 11, 2006
-1-
CHAD THERAPEUTICS, INC.
21622 Plummer Street
Chatsworth, California 91311
(818) 882-0883
ANNUAL MEETING OF SHAREHOLDERS
October 25, 2006
PROXY STATEMENT
GENERAL INFORMATION
This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of
Directors of CHAD Therapeutics, Inc. (the Company) for use at the Annual Meeting of Shareholders
to be held at the Hilton Woodland Hills Hotel, 6360 Canoga Avenue, Woodland Hills, CA 91367, on
October 25, 2006, at 10:00 a.m., Los Angeles time, and any adjournments thereof (the Meeting).
VOTING AND REVOCABILITY OF PROXY
September 8, 2006, has been fixed as the record date for the determination of shareholders entitled
to notice of and to vote at the Meeting and all adjournments thereof. As of September 8, 2006,
there were 10,168,947 of the Companys Common Shares entitled to a vote at the Meeting. This Proxy
Statement and the accompanying proxy will first be mailed to shareholders on or about September 11,
2006. The Companys 2006 Annual Report to Shareholders, including financial statements for the
fiscal year ended March 31, 2006, accompanies this report or has previously been mailed to
shareholders entitled to vote at the Meeting.
Proxies may be revoked at any time before they are voted by filing with the Secretary of the
Company a written notice of revocation or by executing a proxy bearing a later date. Proxies may
also be revoked by any shareholder present at the Meeting who expresses a desire to vote his shares
in person. Subject to any such revocation, all shares represented by properly executed proxies will
be voted in accordance with the specifications on the enclosed proxy. If no such specification is
made, the shares will be voted as follows: (1) for the election as directors of each of the
nominees named herein and (2) to ratify the appointment of KPMG LLP, certified public accountants,
as the Companys independent auditors for its fiscal year commencing April 1, 2006. In the event
that any nominee becomes unavailable to serve, the proxy holders presently intend to vote for the
election of the remaining nominees named herein and permit the new Board of Directors to fill any
vacancy that may exist on the Board. However, the proxy holders reserve the right to vote for other
persons if any nominee named herein becomes unavailable to serve and the proxy holders deem it to
be in the best interests of the Company to vote for such other persons.
-2-
Vote Required for Approval
1. Election of Directors
Section 708 of the California Corporations Code provides that a shareholder may vote for one (1) or
more directors by cumulative voting provided that the name of the candidates for whom the
cumulative votes would be cast have been placed in nomination prior to the voting and that the
shareholder has given notice at the Meeting prior to the voting of the shareholders intention to
cumulate his votes. If any one (1) shareholder has given such notice, all shareholders may cumulate
their votes for the election of directors. Cumulative voting means that each shareholder is
entitled to as many votes as equal the number of shares that he owns multiplied by the number of
directors to be elected. He may cast all of such votes for a single nominee or he may distribute
them among any two (2) or more nominees, as he sees fit. If cumulative voting is not requested,
each shareholder will be entitled to one (1) vote per share for each director to be elected.
The enclosed proxy vests in the proxy holders cumulative voting rights. The persons authorized to
vote shares represented by executed proxies in the enclosed form (if authority to vote for the
election of directors is not withheld) will have full discretion and authority to vote cumulatively
and to allocate votes among any or all of the Board of Directors nominees as they may determine
or, if authority to vote for a specified candidate or candidates has been withheld, among those
candidates for whom authority to vote has not been withheld. In any case, the proxies may be voted
for less than the entire number of nominees if any situation arises which, in the opinion of the
proxy holders, makes such action necessary or desirable. The three (3) nominees who receive the
largest number of votes shall be elected.
2. Other Matters
On any other matters which may come before the Meeting, shareholders will be entitled to one (1)
vote for each share held of record. Approval of the proposal to ratify the appointment of KPMG LLP,
certified public accountants, requires the affirmative vote of a majority of the Common Shares
represented and voting at the Meeting.
The presence in person or proxy of the persons entitled to vote a majority of the issued and
outstanding Common Shares constitutes a quorum for the transaction of business at the Meeting.
3. Abstentions and Broker Non-votes
Abstentions and shares held by brokers that are present in person or by proxy but that are not
voted because the brokers were prohibited from exercising discretionary authority (broker
non-votes) will be counted for the purpose of determining whether a quorum is present for the
transaction of business. Abstentions and broker non-votes can have the effect of preventing
approval of a proposal where the number of affirmative votes, though a majority of the votes that
are cast, does not constitute a majority of the required quorum. All votes will be tabulated by the
inspector of election appointed for the 2006 annual meeting, who will separately tabulate
affirmative and negative votes, abstentions, and broker non-votes.
-3-
VOTING SECURITIES AND PRINCIPAL HOLDERS THEREOF
The following table sets forth as of August 31, 2006, the ownership of the Common Shares by those
persons known by the Company to own beneficially five percent (5%) or more of such shares, by each
director who owns any such shares, and by all officers and directors of the Company as a group:
|
|
|
|
|
|
|
|
|
|
|
Percent |
Name and Address |
|
Amount |
|
Owned |
Thomas E. Jones |
|
|
330,775 |
|
|
|
3.3 |
% |
Earl L. Yager |
|
|
282,434 |
|
|
|
2.8 |
% |
John C. Boyd |
|
|
188,129 |
|
|
|
1.9 |
% |
Philip T. Wolfstein |
|
|
185,497 |
|
|
|
1.8 |
% |
James M. Brophy |
|
|
53,579 |
|
|
|
0.5 |
% |
Kathleen M. Griggs |
|
|
27,405 |
|
|
|
0.3 |
% |
All Officers & Directors as a group (11 people) |
|
|
1,407,476 |
|
|
|
13.8 |
% |
Kevin Kimberlin (3) |
|
|
836,560 |
|
|
|
8.2 |
% |
|
|
|
(1) |
|
The address of each director is 21622 Plummer Street, Chatsworth, CA 91311. |
|
(2) |
|
Includes shares subject to options which are currently exercisable or which become exercisable
within sixty (60) days: Thomas E. Jones 127,779 shares,
John C. Boyd 62,485 shares, Philip T.
Wolfstein 68,665 shares, James M. Brophy 43,174 shares,
Kathleen M. Griggs 15,000 shares,
Earl L. Yager 88,107 shares, all Officers and Directors as a group 558,210 shares. |
|
(3) |
|
Mr. Kimberlins address is c/o Spencer Trask, 535 Madison Avenue, New York, NY 10022. |
PROPOSAL NO. 1: ELECTION OF DIRECTORS
Nominees
The Bylaws of the Company, as amended, provide that the Board of Directors shall not be less than
five (5) and not more than thirteen (13) and shall be fixed from time to time by resolution of the
Board of Directors (Board). At a meeting held on August 10, 2006, the Board of Directors fixed
the number of directors constituting the entire Board at six (6).
The Bylaws divide the Board into two (2) classes, Class I and Class II. Three (3) directors have
terms of office that expire at the 2006 Annual Meeting; these three (3) directors are standing for
reelection for a two-year term as Class II members. These directors are Messrs. Jones, Boyd, and
Yager.
The remaining Class I members will continue to serve until the 2007 Annual Meeting.
It is the intention of the persons named in the proxy to vote such proxies for the election of the
three (3) listed nominees, each of whom has consented to be a nominee and serve as a director if
elected. In the event that any nominee becomes unavailable to serve, the proxy holders presently
intend to vote for the election of the remaining nominees named herein and permit the new Board
of Directors to fill any vacancy that may exist on the Board. However, the proxy holders reserve
the right to vote for other persons if any nominee named herein becomes unavailable to serve and
the proxy holders deem it to be in the best interests of the Company to vote for such other
persons.
-4-
The nominees for election to Class II and the incumbents in Class I have supplied the following
information pertaining to their age and principal occupation or employment during the past five (5)
years:
|
|
|
|
|
|
|
|
|
|
|
Name |
|
Age |
|
Position |
|
Director Since |
Nominees to Class II |
|
|
|
|
|
|
|
|
|
|
Thomas E. Jones
|
|
|
62 |
|
|
Chairman and Director
|
|
|
1997 |
|
John C. Boyd (2)(3)
|
|
|
73 |
|
|
Director
|
|
|
1986 |
|
Earl L. Yager
|
|
|
60 |
|
|
Chief Executive Officer,
President and Director
|
|
|
1988 |
|
Incumbents in Class I |
|
|
|
|
|
|
|
|
|
|
Philip T. Wolfstein (1)(2)(3)
|
|
|
55 |
|
|
Director
|
|
|
1994 |
|
James M. Brophy (1)(2)(3)
|
|
|
56 |
|
|
Director
|
|
|
2000 |
|
Kathleen M. Griggs (1)(3)(4)
|
|
|
51 |
|
|
Director
|
|
|
2003 |
|
|
|
|
(1) |
|
Member of Audit Committee |
|
(2) |
|
Member of Compensation Committee |
|
(3) |
|
Member of Corporate Governance Committee |
|
(4) |
|
Audit Committee Expert |
Nominees to Class II
Thomas E. Jones was elected Chairman effective January 1, 2003, and was Chief Executive Officer of
the Company from April 1, 1998 to March 31, 2004, and a director since October 1997. From 1996 to
1997, Mr. Jones was an independent consultant to numerous companies in the health care field,
including the Company from March 1997. From 1973 to 1996, Mr. Jones was employed by Nellcor Puritan
Bennett Corporation and its predecessor, Puritan Bennett, Inc., a major manufacturer of respiratory
products where Mr. Jones served in a number of positions leading up to Senior Vice President and
General Manager of home care business from 1989 to 1996. Mr. Jones was a director of the Compressed
Gas Association for 16 years, including a one-year term as Chairman, and was a director of the
International Oxygen Manufacturers Association for eight (8) years. Mr. Jones is currently a member
of the Engineering Advisory Board at the University of Kansas.
John C. Boyd has been a director of the Company since May 1986. Prior to his retirement in 1994,
Mr. Boyd was General Manager of Dunaway Equipment Co., Inc., a company specializing in the sale and
service of equipment in the logging industry. From 1982 to 1991, Mr. Boyd was President of Beaty
Leasing & Rental, an automobile leasing and rental firm which he founded. From 1969 to 1982, he
served as Personnel Director and Manager of Marketing Administration for Riker Laboratories, Inc.,
a major manufacturer and distributor of pharmaceuticals and health care products.
Earl L. Yager has served as a director of the Company since July 1988. Mr. Yager was appointed
Chief Executive Officer effective April 1, 2004, and has served as the President of the Company
since January 2003. Mr. Yager has also served as the Companys Chief Operating Officer from
September 2000 to April 2004, Executive Vice President from April 1999 to September 2000, Senior
Vice President from April 1995 to September 2000, and as Chief Financial Officer from May 1983 to
April 2004. Mr. Yager has been a certified public accountant since 1970 and is a member of the
American Institute of Certified Public Accountants.
-5-
Incumbents in Class I
James M. Brophy has been a director of the Company since September 2000. Mr. Brophy is a hospital
executive and from 2003 to 2005 he was the Senior Vice President of Truman Medical Centers. From
2001 to 2002, Mr. Brophy was the President of Missouri Baptist Medical Center. In 2000, Mr. Brophy
was the Deputy Executive Director of Truman Medical Centers and from 1992 to 1999, Mr. Brophy was
President of Saint Lukes Northland and St. Lukes Hospitals. Mr. Brophy has served in the health
care field as a senior executive and administrator since 1974. Mr. Brophy is currently a Fellow of
the American College of Healthcare Executives and is a past member of the Board of Directors of
HealthNet, Premier Alliance Insurance Company and the Illinois Hospital Association.
Kathleen M. Griggs has served as a director of the Company since September 2003. Ms. Griggs is
currently a financial consultant and served as the Executive Vice President and Chief Financial
Officer of SonicWALL, Inc., a publicly held Internet security system manufacturer from July 2003 to
October 2004. Ms. Griggs served as Executive Vice President and Chief Financial Officer of QAD
Inc., a publicly held provider of enterprise resource planning software, from March of 2000 to July
of 2003. From 1999 to 2000, Ms. Griggs served as the chief financial officer of Adept Technology, a
publicly held automation software and hardware manufacturer in San Jose, California. From 1997 to
1999, she served as CFO for Borland Software Corporation, a publicly held software company. Prior
to that, she was employed in several positions in accounting and financial management. Ms. Griggs
has served as the Chief Financial Officer of publicly held companies for a total of eight (8) years
and the Corporate Governance Committee has determined she has the expertise to serve as Chairman of
the Audit Committee. Ms. Griggs received a Bachelor of Science degree in Business Administration
from the University of Redlands and a Master of Business Administration degree from the University
of Southern California in Los Angeles.
Philip T. Wolfstein has been a director of the Company since October 1994. As of April 2005, Mr.
Wolfstein is an International Trade consultant. From July 2004 to 2005, Mr. Wolfstein was Executive
Vice President of Sales, Marketing and Business Development for Bay World, Ltd. and, from June 2001
to 2004, was Managing Director, Southern California, for PM Global Food LLC. From 1976 to 2001, he
was President and a Director of Wolfstein International, Inc., an international trading company.
Mr. Wolfstein served on the Executive Committee of the United States Meat Export Federation (USMEF)
from 1998 to 2004 and held all Board positions from Representative to Chairman from November 1997
to 2003. He is also a member of the USMEFs exporter committee and remains actively engaged in
eliminating trade barriers for U.S. products.
Information Concerning Board of Directors and Certain Committees
The Board of Directors holds regular meetings and held a total of twelve (12) meetings during the
fiscal year ended March 31, 2006. All of the then current directors attended or participated in
75% or more of the aggregate of (i) the total number of meetings of our Board of Directors and (ii)
the total number of meetings held by all committees of our Board of Directors on which such
director served in fiscal 2006.
Three (3) committees have been created by the Board of Directors an Audit Committee, a
Compensation Committee, and a Corporate Governance Committee. The members of the Audit Committee
are Ms. Griggs and Messrs. Brophy and Wolfstein. Ms. Griggs is the Chairman of the Audit Committee.
The Board of Directors has determined that Ms. Griggs is an audit committee financial expert as
defined in Item 401(h) of Regulation S-K. Each member of the Audit Committee is an independent
director as defined in the rules of the American Stock Exchange and also meets the additional
criteria for independence of Audit Committee members set forth in Rule 10A-3(b)(1) under the
Securities Exchange Act of 1934, as amended. The Audit Committee met five (5) times during the
fiscal year ended March 31, 2006.
-6-
The members of the Compensation Committee are Messrs. Boyd, Brophy, and Wolfstein. Mr. Wolfstein is
the Chairman of the Compensation Committee. Each member of the Compensation Committee is an
independent director as defined in the rules of the American Stock Exchange. The Compensation
Committee met four (4) times during the fiscal year ended March 31, 2006.
The members of the Corporate Governance Committee are Messrs. Boyd, Brophy, Wolfstein, and Ms.
Griggs. Mr. Brophy is Chairman of the Corporate Governance Committee. The Corporate Governance
Committee met five (5) times during the fiscal year ended March 31, 2006. Each member of the
Corporate Governance Committee is an independent director, as defined in the rules of the
American Stock Exchange.
The Audit Committee has sole authority to appoint, evaluate, and replace the Companys independent
auditors. In addition, the Audit Committee approves in advance all audit engagement fees and all
audit-related, tax and other engagements with the independent auditors. The Audit Committees
duties also include, among other things, reviewing and making recommendations to the Board of
Directors with respect to (1) the policies and procedures of the Company and management with
respect to maintaining the Companys books and records and furnishing necessary information to the
independent auditors, and (2) the adequacy of the Companys internal accounting controls. The Audit
Committee confers with the independent auditors regarding the operation and performance of the
Companys financial reporting systems and personnel. The Company has adopted a charter governing
the functions of the Audit Committee in accordance with SEC guidelines.
The functions of the Compensation Committee include making recommendations to the Board of
Directors regarding compensation for the principal officers and other key employees of the Company,
incentive compensation to employees, and other employee compensation and benefits. In addition, the
Compensation Committee reviews and approves the base salary, incentive compensation, and long-term
compensation payable to the Companys Chief Executive Officer. All options and other equity
incentives granted to officers or employees of the Company are approved by the Compensation
Committee.
The functions of the Corporate Governance Committee include the identification, screening and
recommendation of candidates for the Companys Board of Directors; the composition and function of
board committees; and the compensation and benefits to be offered to board members, reviewing and
making recommendations regarding succession and replacement of key executives and the Companys
code of conduct, and other matters regarding corporate structure and
organization. When considering a potential candidate for membership on the Board of Directors, the
Corporate Governance Committee considers the candidates relevant business, professional, and
industry experience, demonstrated character and judgment, and prior experience serving as a
director. The Corporate Governance Committee may also consider other factors as it may deem
appropriate in the evaluation of potential nominees. The Company has adopted a charter governing
the functions of the Corporate Governance Committee which is available on the Companys website.
The Corporate Governance Committee recommended to the Board of Directors the nomination of
directors for the 2006 annual meeting.
The Corporate Governance Committee will also consider recommendations for nominees to the Board of
Directors submitted by shareholders. Shareholders who wish the Corporate Governance Committee to
consider their recommendations for nominees for the position of director should submit the
candidates name, appropriate biographical information, a brief description of such candidates
qualifications, and such candidates written consent to nomination to the Corporate Governance
Committee in care of James M. Brophy, the Chairman of the Corporate Governance Committee, at the
Companys headquarters.
Each non-employee director is entitled to receive his expenses and a fee of $1,000 for each Board
meeting attended and $100 for each committee meeting attended unless the committee meeting occurs
on the same day as the Board meeting, in which event, each non-employee director receives only the
fee for attending a Board meeting. In addition, each non-employee director receives a quarterly
retainer in the amount of $2,500, and the
-7-
Audit Committee chairman receives a quarterly retainer in the amount of $3,250. Non-employee
directors may receive equity grants upon their election to the Board and receive annual, restricted
stock grants for common shares having a value of $20,000 on the date of the grant. Directors who
are also employees do not receive separate compensation for services as directors.
Section 16 Beneficial Ownership Reporting
Under the Federal securities laws, the Companys directors, its executive officers, and any persons
holding more than ten (10) percent of the Companys common stock are required to report their
ownership of the Companys common stock and any changes in that ownership to the Securities and
Exchange Commission on Form 3, for an initial report of securities ownership, and on Forms 4 or 5,
for reports of changes in security ownership. Such directors, executive officers, and ten (10)
percent shareholders are also required by Securities and Exchange Commission rules to furnish the
Company with copies of all Section 16(a) forms they file. Specific due dates for these reports have
been established, and the Company is required to report in this Proxy Statement any failure to file
by these dates during the most recent fiscal year or prior fiscal years. Based on the written
representations of its directors and executive officers and its ten (10) percent shareholders and
copies of the reports that they have furnished to the Company, the Company believes that the
Companys directors and executive officers and ten (10) percent shareholders timely filed all
reports required under Section 16(a) in fiscal 2006.
Code of Ethics
We have adopted a Code of Business Conduct and Ethics that applies to our employees (including our
principal executive officer, chief financial officer and controller). A copy of our Code of
Business Conduct and Ethics can be found under the Investor Relations section of our website at
www.chadtherapeutics.com. The information on our website is not incorporated by
reference in this Proxy Statement. We may post amendments to, or waivers of, the provisions of the
Code of Business Conduct and Ethics, if any, made with respect to any of our directors and
executive officers on that website.
Recommendation of the Board of Directors
The Companys Board of Directors unanimously recommends that the shareholders vote FOR the election
of the nominees named above.
PROPOSAL NO. 2: INDEPENDENT AUDITORS
The Board of Directors has appointed, subject to ratification by the shareholders, KPMG LLP as
independent auditors for the fiscal year commencing April 1, 2006. A representative of KPMG LLP is
expected to attend the Meeting to make any statements he may desire and respond to shareholders
questions.
-8-
During the fiscal years ended March 31, 2006 and 2005, KPMG LLP provided various audit,
audit-related, and non-audit services to us as follows:
|
|
|
|
|
|
|
|
|
Fee Category |
|
Fiscal 2006 Fees |
|
|
Fiscal 2005 Fees |
|
Audit Fees Aggregate
fees billed for
professional services
rendered for the audit
of our 2006 and 2005
fiscal year annual
financial statements
and review of financial
statements included in
our quarterly reports
on Form 10-Q or
services that are
normally provided in
connection with
statutory and
regulatory filings or
engagements for the
2006 and 2005 fiscal
years. |
|
$ |
154,000 |
|
|
$ |
145,150 |
|
|
|
|
|
|
|
|
|
|
Audit-Related
Fees
Aggregate fees billed
for assurance and
related services that
are reasonably related
to the performance of
the audit or review of
our financial
statements which are
not reported under
Audit Fees above. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax Fees Aggregate
fees billed for tax
compliance and tax
planning. |
|
|
21,500 |
|
|
|
17,750 |
|
|
|
|
|
|
|
|
|
|
All Other Fees
Aggregate fees billed
for products and
services provided other
than as described in
the preceding three (3)
categories. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Fees |
|
$ |
175,500 |
|
|
$ |
162,900 |
|
|
|
|
|
|
|
|
Our Audit Committee has considered whether provision of the above services other than audit
services is compatible with maintaining the independent accountants independence and has
determined that such services have not adversely affected KPMG LLPs independence.
Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent
Accountants
The Audit Committees policy is to pre-approve all audit and permissible non-audit services
provided by the independent accountants. These services may include audit services, audit-related
services, tax services and other services. Pre-approval is generally provided for up to one (1)
year, and any pre-approval is detailed as to the particular service or category of services and is
generally subject to a specific budget. The independent accountants and management are required to
periodically report to the Audit Committee regarding the extent of services provided by the
independent accountants in accordance with this pre-approval and the fees for the services
performed to date. The Audit Committee may also pre-approve particular services on a case-by-case
basis.
Since the May 6, 2003 effective date of the Securities and Exchange Commission rules stating that
an auditor is not independent of an audit client if the services it provides to the client are not
appropriately approved, each new engagement of KPMG LLP was approved in advance by the Audit
Committee, and none of those engagements made use of the de minimus exception to pre-approval
contained in the SECs rules.
-9-
Recommendation of the Board of Directors
The Board of Directors unanimously recommends that the shareholders vote FOR the ratification of
the appointment of KPMG LLP as the Companys independent auditors for the fiscal year ending March
31, 2007.
AUDIT COMMITTEE REPORT
The following is the report of the Audit Committee of the Board of Directors of the Company. The
information contained in this report shall not be deemed to be soliciting material or to be
filed with the Securities and Exchange Commission, nor shall such information be incorporated by
reference into any future filing under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates
it by reference in such filing.
On behalf of the Board of Directors, the Audit Committee monitors the Companys financial reporting
processes and internal controls, as well as the Companys relationship with its independent
accountants and the performance of such accountants. All of the members of the Audit Committee are
independent directors, and the Chairman of the Audit Committee has been determined to have the
expertise to serve as chairman by the Corporate Governance Committee. The Board of Directors has
adopted a charter for the Audit Committee, which can be accessed under the Investor Relations
section on CHADs website.
Management has the primary responsibility for preparation of the Companys financial reports, the
Companys financial reporting systems, and its internal controls. The Audit Committee is not
intended to supersede in any respect managements responsibilities in this regard. Management
has represented to the Audit Committee that the Companys financial statements were prepared in
accordance with generally accepted accounting principles, and the Audit Committee has reviewed and
discussed such financial statements with management and with the Companys independent accountants.
The Audit Committee has also discussed with the independent accountants their evaluation of the
Companys financial reporting systems and internal controls, their plan of audit for fiscal 2006,
the application of new accounting principles to the Companys financial statements, and other
matters required to be communicated to the Committee by the independent accountants pursuant to
standards established by the American Institute of Certified Public Accountants.
The Audit Committee has received from the independent accountants a letter addressing matters which
might bear on the independence of the accountants as required by Independence Standards Board
Standard No. 1. The Audit Committee has discussed independence issues with the accountants and has
reviewed their fees and scope of services rendered to the Company. The Audit Committee has
discussed the performance of the independent accountants with the Companys management. The Audit
Committee has satisfied itself as to the auditors independence.
In reliance on the foregoing, the Audit Committee has recommended to the Board of Directors the
inclusion of the audited financial statements in the Companys Annual Report on Form 10-K for the
year ended March 31, 2006.
Submitted by the Audit Committee of the Board of Directors,
Kathleen M. Griggs, Chairman
James M. Brophy
Philip T. Wolfstein
-10-
EXECUTIVE OFFICERS
The executive officers of the Company are:
|
|
|
|
|
|
|
Name |
| |
Age |
|
Position |
Thomas E. Jones
|
|
|
62 |
|
|
Chairman |
Earl L. Yager
|
|
|
60 |
|
|
President and Chief Executive Officer |
Oscar J. Sanchez
|
|
|
64 |
|
|
Vice President, Business Development |
Alfonso Del Toro
|
|
|
48 |
|
|
Vice President, Manufacturing |
Kevin McCulloh
|
|
|
45 |
|
|
Vice President, Engineering |
Erika Laskey
|
|
|
40 |
|
|
Vice President, Sales and Marketing |
Tracy Kern
|
|
|
38 |
|
|
Chief Financial Officer |
Samuel Patton
|
|
|
45 |
|
|
Vice President, Quality Assurance
and Regulatory Affairs |
Paula OConnor
|
|
|
53 |
|
|
Secretary |
Oscar J. Sanchez was appointed Vice President of Business Development of the Company in March 2000.
Mr. Sanchez served as the Companys Vice President of Engineering and
Development from September 1996 to February 2000, Vice President of Manufacturing from April 1993
to August 1996, and Manufacturing Manager from April 1983 to April 1993. Prior to these assignments
with the Company, Mr. Sanchez occupied various positions of responsibility in Engineering and
Management both inside and outside the U.S., the most recent as Director of Manufacturing for Riker
Laboratories in Mexico City. Mr. Sanchez has been an active member of the Society of Manufacturing
Engineers for 20 years where he served two (2) terms as elected Chairman of the Los Angeles
Chapter.
Alfonso Del Toro was appointed Vice President, Manufacturing of the Company in January 1998. Mr.
Del Toro was the Companys Manufacturing Manager from January 1997 to December 1997. From 1993 to
1996, Mr. Del Toro was Manufacturing Manager for VIA Medical Corp. From 1986 to 1993, Mr. Del Toro
was employed by Nellcor, Inc., a major manufacturer of respiratory products where he served in
several positions leading up to Senior Principal Manufacturing Engineer.
Kevin McCulloh was appointed Vice President of Engineering of the Company in March 2000. Mr.
McCulloh was Engineering Manager from March 1999 to February 2000, and was Manufacturing Engineer
from July 1998, when he joined the Company, to March 1999. From 1982 to 1998, Mr. McCulloh was
employed by Litton Life Support where he had broad based experience in product design and
development leading up to the position of Senior Design Engineer.
Erika Laskey was appointed Vice President of Sales and Marketing of the Company in April 2002. Ms.
Laskey was Director of Sales and Marketing from January 2001 to March 2002. From 1992 to 2000, Ms.
Laskey was employed by Mallinckrodt, Inc. (formerly Nellcor Puritan-Bennett) where she held a
number of sales positions leading up to the position of Global Account Business Manager.
Tracy Kern was appointed Chief Financial Officer in April 2004. Ms. Kern was Cost Accounting
Manager from January 2003 to March 2004. From 1997 to 2002, Ms. Kern was employed by KPMG LLP,
where she held a number of positions leading up to the position of Audit Manager. Ms. Kern is a
certified public accountant.
Samuel Patton was appointed Vice President, Quality Assurance and Regulatory Affairs in April 2005.
Mr. Patton was an independent consultant in the quality systems area for the health care field from
January 2004 to March 2005. From 2000 to 2003 Mr. Patton was employed by Medtronic, Inc. as
Director of Cardiac Rhythm Management Global Quality Systems.
-11-
Paula OConnor was appointed Secretary in September 2004. Ms. OConnor has been Executive Assistant
to the Chairman and Chief Executive Officer since June 1998.
For the biographies of Messrs. Jones and Yager, see Directors.
SUMMARY COMPENSATION TABLE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-Term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation |
|
|
|
|
Annual |
|
|
|
|
|
Awards |
|
|
|
|
Compensation |
|
|
|
|
|
Securities |
|
All Other |
|
|
Salary Bonus (1) |
|
|
|
|
|
Underlying Options |
|
Compensation |
Name and |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) |
Principal Position |
|
Year |
|
($) |
|
($) |
|
(#) |
|
($) |
Thomas E. Jones,
Chairman |
|
|
2006 |
|
|
|
160,008 |
|
|
|
|
|
|
|
|
|
|
|
7,550 |
|
|
|
|
2005 |
|
|
|
160,000 |
|
|
|
24,000 |
|
|
|
|
|
|
|
3,450 |
|
|
|
|
2004 |
|
|
|
160,000 |
|
|
|
|
|
|
|
|
|
|
|
10,583 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earl L. Yager
President and Chief Executive Officer |
|
|
2006 |
|
|
|
240,000 |
|
|
|
|
|
|
|
|
|
|
|
3,000 |
|
|
|
|
2005 |
|
|
|
235,500 |
|
|
|
24,975 |
|
|
|
|
|
|
|
7,500 |
|
|
|
|
2004 |
|
|
|
222,000 |
|
|
|
|
|
|
|
|
|
|
|
7,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alfonso Del Toro
Vice President, Manufacturing |
|
|
2006 |
|
|
|
142,200 |
|
|
|
|
|
|
|
|
|
|
|
7,052 |
|
|
|
|
2005 |
|
|
|
138,000 |
|
|
|
12,420 |
|
|
|
|
|
|
|
6,500 |
|
|
|
|
2004 |
|
|
|
138,000 |
|
|
|
8,694 |
|
|
|
|
|
|
|
6,098 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kevin McCulloh
Vice President, Engineering |
|
|
2006 |
|
|
|
148,800 |
|
|
|
|
|
|
|
|
|
|
|
7,135 |
|
|
|
|
2005 |
|
|
|
138,000 |
|
|
|
16,560 |
|
|
|
|
|
|
|
6,500 |
|
|
|
|
2004 |
|
|
|
138,000 |
|
|
|
8,694 |
|
|
|
|
|
|
|
6,098 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Erika Laskey
Vice President, Sales and Marketing |
|
|
2006 |
|
|
|
169,200 |
|
|
|
27,554 |
|
|
|
|
|
|
|
6,991 |
|
|
|
|
2005 |
|
|
|
163,560 |
|
|
|
33,000 |
|
|
|
|
|
|
|
6,500 |
|
|
|
|
2004 |
|
|
|
166,290 |
|
|
|
32,346 |
|
|
|
|
|
|
|
5,953 |
|
|
|
|
(1) |
|
Annual bonus amounts are earned and accrued during the fiscal years indicated and paid within
30 days subsequent to the end of the fiscal year indicated. |
|
(2) |
|
These amounts consist of contributions by the Company in 2006, 2005, and 2004 to the CHAD
Therapeutics, Inc. Employee Savings and Retirement Plan. |
-12-
Option Grants for the Year Ended March 31, 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% of Total |
|
|
|
|
|
|
|
|
|
|
Potential Realized Value |
|
|
|
|
|
|
|
Options |
|
|
|
|
|
|
|
|
|
|
at Assumed Annual Rates |
|
|
|
Options |
|
|
Granted to |
|
|
Exercise |
|
|
|
|
|
|
of Stock Price Appreciation |
|
|
|
Granted (#) |
|
|
Employees |
|
|
Price ($) Per |
|
|
Expiration |
|
|
for Option Term |
|
Name |
|
(#) |
|
|
During 2006 |
|
|
Share |
|
|
Date |
|
|
5% |
|
|
10% |
|
NONE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregated Option Exercises in Last Fiscal and Option Values at March 31, 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value of Unexercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-The-Money |
|
|
|
|
|
|
|
|
|
|
Number of Securities |
|
Options |
|
|
Shares |
|
|
|
|
|
Underlying Unexercised |
|
at March 31, 2006 |
|
|
Acquired on |
|
Value |
|
Options at March 31, 2006 |
|
Exercisable |
Name |
|
Exercise (#) |
|
Realized ($) |
|
Exercisable/Unexercisable |
|
Unexercisable($) |
Thomas E. Jones |
|
|
-0- |
|
|
|
-0- |
|
|
|
128,000 / |
|
|
|
210,000 /-0- |
|
Earl L. Yager |
|
|
-0- |
|
|
|
-0- |
|
|
|
88,000 / |
|
|
|
150,000 /-0- |
|
Alfonso Del Toro |
|
|
-0- |
|
|
|
-0- |
|
|
|
40,000 / |
|
|
|
73,000 /-0- |
|
Kevin McCulloh |
|
|
-0- |
|
|
|
-0- |
|
|
|
41,000 / |
|
|
|
62,000 /-0- |
|
Erika Laskey |
|
|
-0- |
|
|
|
-0- |
|
|
|
31,000 / 9,000 |
|
|
|
23,000 / 16,000 |
|
Compensation Committee Interlocks and Insider Participation
None of the members of the Compensation Committee are, or formerly were, officers or employees of
the Company or had any relationship requiring disclosure under Item 404 of Regulation S-K.
Furthermore, none of the executive officers of the Company served as a member of the Board of
Directors, Compensation Committee or committee performing equivalent functions of any other public
company.
Employment Agreement
Effective April 1, 1998, the Company and Thomas E. Jones entered into an employment agreement,
which was amended on January 1, 2003, pursuant to which the Company employs Mr. Jones as Chairman
of the Board of Directors (the Employment Agreement). The Employment Agreement, as amended,
provides a base salary of $160,000 per year, which amount is subject to annual review by the Board
of Directors. In addition, Mr. Jones is eligible to receive a bonus in an amount to be determined
by the Board of Directors. Mr. Jones is entitled to participate in all stock option, severance, and
benefit plans adopted by the Company.
The Employment Agreement does not have a specific term. The Employment Agreement may be terminated
at any time by the Company, with or without cause, and may be terminated by Mr. Jones upon 90 days
notice. If
-13-
Mr. Jones resigns or is terminated for cause (as defined in the Employment Agreement), he is
entitled to receive only his base salary and accrued vacation through the effective date of his
resignation or termination. If Mr. Jones is terminated without cause, he is entitled to receive a
severance benefit in accordance with the Companys Severance and Change of Control Plan (the
Plan) or, if such Plan is not applicable, a severance benefit equal to 200% of his salary and
incentive bonus for the prior fiscal year. A description of the Plan is set forth below.
Severance and Change of Control Plan
The Company has adopted a Severance and Change of Control Plan pursuant to which eight (8) of the
Companys officers have entered into Severance and Change of Control Agreements with the Company
(the Severance Agreements). The Severance Agreements provide that, if a senior executive officer
is terminated without cause after a change in control of the Company, or if such
officer suffers an adverse change in his duties, then the officer is entitled to a lump sum
severance benefit equal to the greater of (i) 200% of his aggregate compensation for the prior
calendar year or (ii) 200% of his deemed compensation for the year of termination, calculated in
accordance with the terms of the Severance Agreement. Junior officers are entitled to lower
severance benefits, based upon their level of seniority. If any payment due a named executive
officer pursuant to the Severance Agreements would be deemed an excess parachute payment under
Section 280G of the Internal Revenue Code, then the Company may reduce such payment to the extent
necessary to avoid all taxes and penalties under Section 280G. Separately, the Company provided for
accelerated vesting of all outstanding options upon a Change of Control or Ownership Change of the
Company.
An adverse change in duties is defined in the Severance Agreements to include, among other things,
an involuntary reduction in authority, any reduction in annual salary, a reduction of 10% or more
in aggregate compensation or re-location to a site more than 50 miles from the executives
principal place of employment.
A Change of Control or Ownership Change shall be deemed to have occurred if (i) as a result of a
tender offer or sale of stock any person acquires 20% or more of the Companys Common Stock, (ii)
the Company merges into another corporation or, as a result of a merger, shareholders of the
Company own less than 70% of the voting stock of the surviving entity, (iii) more than one third of
the Companys directors are replaced during any 12-month period by directors who were not endorsed
by a majority of the Board, (iv) the Company is dissolved or sells substantially all of its assets,
or (v) any other event occurs which the Board of Directors deems to constitute an Ownership Change.
-14-
EQUITY COMPENSATION PLAN INFORMATION
The following table provides information as of March 31, 2006, with respect to the shares of our
common stock that may be issued under our existing equity compensation plans.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Securities |
|
|
|
|
|
|
|
|
|
|
Remaining Available for |
|
|
Number of Securities to be |
|
Weighted-Average |
|
Future Issuance Under |
|
|
Issued Upon Exercise of |
|
Exercise Price of Equity |
|
Compensation Plans |
Plan |
|
Outstanding Options, |
|
Outstanding Options, |
|
[Excluding Securities |
Category |
|
Warrants and Rights |
|
Warrants and Rights |
|
Reflected in Column (a)] |
|
|
(a) |
|
(b) |
|
(c) |
1994 Stock
Option Plan |
|
|
940,000 |
|
|
$ |
2.53 |
|
|
|
-0- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2004 Equity
Compensation
Plan |
|
|
45,000 |
|
|
$ |
3.90 |
|
|
|
705,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
985,000 |
|
|
|
|
|
|
|
705,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORT OF THE COMPENSATION COMMITTEE
The information contained in this report is not to be deemed soliciting material or to be filed
with the Securities and Exchange Commission, nor is such information to be incorporated by
reference into any future filing under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended, except to the extent the Company specifically incorporates it by
reference.
All members of the Compensation Committee are independent, non-employee directors. The Compensation
Committee is responsible for determining the compensation of the Companys Chief Executive Officer.
In addition, the Compensation Committee is responsible for reviewing the Companys compensation
policies and making recommendations to the Board with respect to compensation of other officers.
The Companys compensation policies are designed to:
Attract and retain well-qualified executives who are willing to work in a small company that is
seeking to grow through the development of innovative health care products;
Create a performance-oriented environment which both recognizes and balances annual and
long-term objectives;
Strengthen the identification of executive officers with shareholder interests; and
Reward long-term commitment to the Company.
Compensation of the Companys executive officers is composed primarily of salary, annual incentive
bonuses, and equity grants.
-15-
1. Salaries Salaries for executive officers are established with a view toward maintaining the
Companys competitive ability to retain well-qualified executive officers. The Compensation
Committee reviews the Report on Executive Compensation In the Medical Equipment and Supply Industry
(the Report on Executive Compensation) as reported by Top Five Data Services in establishing
salaries for its executive officers. The Report on Executive Compensation reports on the execution
compensation of 300 U.S. based, publicly traded companies in the medical equipment and supply
industry. The Compensation Committee generally seeks to fix executive salaries at or near the
midpoint for positions of comparable responsibility pursuant to the Report on Executive
Compensation. In addition, the Compensation Committee reviews executive pay in relation to
competitive salaries in the Southern California area. Salaries are reviewed annually by the
Compensation Committee, which consults with the Chief Executive Officer on the appropriate salary
levels for each of the executive officers. Salary levels are generally increased as executives
assume new or expanded responsibilities.
2. Bonuses The Company has an incentive bonus plan with specific performance objectives. Bonuses
are payable yearly, based upon the extent to which the specified performance objectives have been
satisfied. Thirty percent of the target amount is based on the achievement of sales, forty percent
is based on earnings before income taxes and thirty percent is based on individual job performance
objectives. The corporate and individual performance objectives are approved by the Compensation
Committee. The Vice President for Sales and Marketing has a
separate compensation plan that includes a base salary plus incentive compensation based on
achievement of sales targets. Please refer to the Summary Compensation Table for bonuses paid
during the past three years.
3. Equity Grants Equity Grants are intended to strengthen the identification of executive
officers with the interests of the Companys shareholders. Equity grants are used by the
Compensation Committee as a form of long-term incentive compensation and not as remuneration for
the past years services. Equity grants are also issued to a broad range of employees for the
purpose of strengthening the relationship between the employees and the Company. The Compensation
Committee makes equity grants and fixes their terms subject to the provisions of the Companys
equity compensation plan adopted on September 9, 2004. There are no fixed performance criteria that
govern the equity grants. The Compensation Committees standards for determining the number of
equity grants are subjective. The Compensation Committee confers with the Chief Executive Officer
regarding the contribution which each executive officer made to the Companys performance during
previous years and likely future contributions in order to determine if equity grants should be
made and, if so, the appropriate amount to be granted. The Compensation Committee generally makes
grants as a reward for sustained superior performance reflected in the Companys operating results
as well as to reward long-term commitment to the Company. Equity grants are generally structured to
provide executives with an incentive to continue with the Company. In this regard, consideration is
given to the number of equity grants and options held by an officer, the exercise price and vesting
dates. All grants are issued at a price not less than the closing price of the stock on the date
that the grant is approved by the Compensation Committee, generally vest over a period of two (2)
to five (5) years and only attain a value if the price of the stock increases. The Compensation
Committee does not delegate any authority with respect to granting stock options or other equity
grants.
Basis for Compensation of the CEO
During the fiscal year ending March 31, 2006, Earl L. Yager received total annual compensation of
$240,000. The factors considered in establishing the base salary, bonus, and equity grants for Mr.
Yager were the same as described above in the description of our compensation policies. The
Committee also notes the following: Mr. Yagers base salary in 2006 reflected an increase of
approximately 5% over his base salary for 2005. This increase was approved in order to maintain Mr.
Yagers base salary at the approximate mid-point for CEOs of comparably sized medical equipment
manufacturers as set forth in the Report on Executive Compensation. No bonus was paid to Mr. Yager
for the 2006 fiscal year. In addition to the sales and earnings before income taxes
-16-
criteria applicable to all persons eligible for an incentive bonus, the personal objectives for Mr.
Yager in fiscal 2006 included maintaining shareholder value and meeting certain product
development, sales and marketing objectives. These specific objectives were not met. Nonetheless,
the Committee noted Mr. Yagers diligent efforts during the past year to cope with the increasingly
difficult competitive and regulatory environment faced by the Company and expressed its confidence
in Mr. Yagers leadership. No equity grants were made to Mr. Yager during the year ended March 31,
2006, as the Committee noted that Mr. Yager has a significant equity stake in the Company; he
currently owns 282,434 shares or options to acquire shares of the Companys common stock.
Compliance with Internal Revenue Code Section 162(m)
Section 162(m) of the Internal Revenue Code disallows a tax deduction to publicly held companies
for compensation paid to certain of their executive officers, to the extent that compensation,
whether payable in cash or stock, exceeds $1 million per covered officer in any fiscal year. The
limitation applies only to compensation that is not considered to be performance-based.
Non-performance-based compensation paid to the Companys executive officers for the 2005 fiscal
year did not exceed the $1 million limit per officer, and the Committee does not anticipate that
any non-performance-based compensation payable in cash to the executive officers for the 2006
fiscal year will exceed that limit. Accordingly, the Committee has decided not to take any action
at this time to limit or restructure the elements of cash compensation payable to the Companys
executive officers but will reconsider this decision should the individual cash compensation of any
executive officer ever approach the $1 million level. The Companys Stock Option Plan has been
structured so that any compensation deemed paid by the Company in connection with the exercise of
option grants made under that plan with an exercise price equal to the fair market value of the
option shares on the grant date will qualify as performance-based compensation that will not be
subject to the $1 million limitation on deductibility.
Submitted by the Compensation Committee
John C. Boyd (Chairman)
Philip T. Wolfstein
James M. Brophy
DATE FOR SUBMISSION OF SHAREHOLDER PROPOSALS FOR 2007 ANNUAL MEETING
Any proposal, relating to a proper subject, which a shareholder may intend to present for action at
the Annual Meeting of Shareholders to be held in September 2007, and which such shareholders may
wish to have included in the proxy materials for such, in accordance with the provisions of Rule
14a-8 promulgated under the Securities Exchange Act of 1934, must be received in proper form by the
Secretary of the Company at 21622 Plummer Street, Chatsworth, California 91311, not later than
March 21, 2007, which is 120 calendar days prior to the anniversary of the mailing date of this
years proxy materials. It is suggested that any such proposal be submitted by certified mail,
return receipt requested.
If a shareholder wishes to present a proposal at our 2007 annual meeting and the proposal is not
intended to be included in the Companys Proxy Statement relating to the 2007 annual meeting, the
shareholder must give advance notice to the Company prior to the deadline for the annual meeting.
In order to be deemed properly presented, the notice of a proposal must be delivered to the
Companys Corporate Secretary no later than June 3, 2007, which is 45 calendar days prior to the
anniversary of the 2006 annual meeting. However, in the event the 2007 annual meeting is called for
a date which is not within 30 days of the anniversary date of the 2006 annual meeting, shareholder
proposals intended for presentation at the 2007 annual meeting must be received by the
-17-
Corporate Secretary no later than the close of business on the tenth (10th) day following the date
on which public announcement of the date of the 2007 annual meeting is first made. If a shareholder
gives notice of such proposal after June 3, 2007, the proxy solicited by the Board of Directors for
the 2007 annual meeting will confer discretionary authority to vote on such proposal at that
meeting, which may include a vote against such shareholder proposal.
OTHER PROPOSED ACTION
The Meeting is called for the purpose set forth in the notice thereof accompanying this Proxy
Statement. Management is not aware of any matters to come before the meeting other than those
stated in this Proxy Statement. However, inasmuch as matters of which management is not aware may
come before the Meeting or any adjournment thereof, the proxies confer discretionary authority with
respect to acting thereon, and the person named in such proxies intends to vote, act, and consent
in accordance with his best judgment with respect thereto.
PERSONS MAKING THE SOLICITATION
The accompanying proxy is solicited by the Board of Directors of the Company. The Company will pay
all expenses of the preparation, printing, and mailing to the shareholders of the enclosed proxy
and accompanying notice.
-18-
ANNUAL MEETING OF SHAREHOLDERS OF
CHAD THERAPEUTICS, INC.
October 25, 2006
Please date, sign and mail
your proxy card in the
envelope provided as soon
as possible.
ê Please
detach along perforated line and mail in the envelope
provided. ê
|
|
|
|
|
|
|
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE
ELECTION OF DIRECTORS AND FOR PROPOSAL 2.
PLEASE SIGN, DATE, AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FOR
|
|
AGAINST
|
|
ABSTAIN |
1. |
Election of Directors:
|
|
|
2. |
|
Proposal to ratify the appointment of KPMG LLP as
Independent Registered Public Accounting Firm for the
fiscal year ending 2007. |
|
o |
|
o |
|
o |
|
|
|
|
|
|
|
o |
|
|
NOMINEES: |
|
|
|
|
|
|
|
|
|
FOR ALL NOMINEES |
¡ |
Thomas E. Jones |
|
|
|
|
3. |
|
In accordance with the discretion of the proxyholders, to act upon all
matters incident to the conduct of the meeting and upon other matters
as may properly come before the meeting. |
|
|
¡ |
John C. Boyd |
|
|
|
|
|
o |
|
WITHHOLD
AUTHORITY FOR ALL NOMINEES |
¡ |
Earl L. Yager |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WHETHER OR NOT YOU ATTEND THE MEETING IN PERSON, PLEASE MARK,
SIGN, DATE AND RETURN THIS PROXY CARD PROMPTLY USING THE
ENCLOSED ENVELOPE SO THAT YOUR STOCK MAY BE REPRESENTED AT
THE ANNUAL MEETING: |
o
|
|
FOR ALL EXCEPT
(See Instructions below) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INSTRUCTIONS:
To withhold authority to vote for any individual nominee(s), mark
FOR ALL EXCEPT and fill in the circle next to each
nominee you wish to withhold, as shown here:
=
|
|
|
|
|
|
To change the address on your account, please check the box
at right and indicate your new address in the address space
above. Please note that changes to the registered name(s)
on the account may not be submitted
via this method.
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature
of Shareholder:
|
|
|
|
Date:
|
|
|
|
Signature of Shareholder:
|
|
|
|
Date:
|
|
|
|
|
|
|
|
|
|
|
|
Note:
|
|
Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full
title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.
|
|
|
CHAD
THERAPEUTICS, INC.
THIS
PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The undersigned hereby revokes all previous proxies, acknowledges receipt of the Notice of
Annual Meeting of Shareholders to be held on October 25, 2006 and the Proxy Statement and
appoints Thomas E. Jones and Earl L. Yager, and either of them, as Proxyholders, with the full
power of substitution, and hereby authorizes them to represent and vote, as designated on the
reverse, all the shares of voting capital stock of Chad Therapeutics, Inc. held of record by the
undersigned at the close of business on September 9, 2006 (and in the case of item 1 to cumulate
and allocate said votes for directors in his discretion), at the Annual Meeting of Shareholders to be
held on October 25, 2006, and at any and all adjournment(s) thereof, with the same force and effect
as the undersigned might or could do if personally present thereat.
The shares represented by this Proxy, when properly executed, will be voted in the manner
directed herein by the undersigned shareholder. IF NO DIRECTION IS MADE, THIS PROXY
WILL BE VOTED FOR ALL THE NOMINEES FOR DIRECTOR AND FOR APPROVAL OF
PROPOSAL 2.
In their discretion the proxyholders are authorized to vote upon such other business as may
properly come before the meeting.
(CONTINUED
AND TO BE SIGNED ON THE REVERSE SIDE)